RayKnowChina Research Map
Shortlist0

JinanShandong First Medical University

Shandong Cancer Hospital and Institute

山东省肿瘤医院

Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shandong Cancer Hospital and Institute

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌8 papers led2 open trials led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌65 papers led1 open trial led
  3. Hepatocellular carcinoma肝细胞癌59 papers led4 open trials led
  4. Stomach cancer胃癌33 papers led1 open trial led
  5. Hepatoblastoma肝母细胞瘤0 papers led
  6. Retinoblastoma视网膜母细胞瘤0 papers led
  7. Osteosarcoma骨肉瘤1 paper led
  8. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  9. Neuroblastoma神经母细胞瘤4 papers led
  10. Ewing sarcoma尤文肉瘤0 papers led
  11. Multiple myeloma多发性骨髓瘤4 papers led
  12. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led

Not listed for: Chordoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 2220232024: 1120242025: 112025

2 hospitals in Jinan for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT07000643

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  2. Recruiting
    Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07340515

    Age 18 years to 70 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AISide effects & quality of life
Departments in papersRadiation oncology
Papers it led8
  1. Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.2026Oral oncology
  2. A Stacked Multimodality Model Based on Functional MRI Features and Deep Learning Radiomics for Predicting the Early Response to Radiotherapy in Nasopharyngeal Carcinoma.2025Academic radiology
  3. Pretreatment multiparametric MRI radiomics-integrated clinical hematological biomarkers can predict early rapid metastasis in patients with nasopharyngeal carcinoma.2024BMC cancerFree full text
  4. The therapeutic utility of combining dynamic contrast-enhanced magnetic resonance imaging with arterial spin labeling in the staging of nasopharyngeal carcinoma.2023BMC medical imagingFree full text
  5. Association of Socioeconomic Disparities With Nasopharyngeal Carcinoma Survival in an Endemic Area, China.2023Cancer control : journal of the Moffitt Cancer CenterFree full text
  6. Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequencing: implications for predicting clinical outcomes.2022Molecular medicine (Cambridge, Mass.)Free full text
  7. Beam complexity and monitor unit efficiency comparison in two different volumetric modulated arc therapy delivery systems using automated planning.2021BMC cancerFree full text
  8. Dosimetry study of nasopharyngeal carcinoma based on Halcyon accelerator fixed-field intensity-modulated radiation therapy.2021Journal of cancer research and therapeutics
Chinese-language papers (not in the count)1
  1. [Study on the assignment method of intensity modulated radiotherapy plan for nasopharyngeal carcinoma based on MR images].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status3
  1. Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal CarcinomaRecruitingNCT07000643Lead (inferred)Phase 3Start 2025-05
  2. Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialRecruitingNCT07340515Lead (inferred)Phase 3Start 2025-12
  3. A Study of ILB2109 and Toripalimab in Patients With Advanced Solid MalignanciesStatus unknownNCT05955105Study sitePhase 1/Phase 2Start 2023-07
More papers found outside PubMed (not counted)12
  1. Intratumoral metabolic heterogeneity on 18F-FDG PET/CT as a biomarker for tumor staging in nasopharyngeal carcinoma2025Clinical and Translational Imagingarticle
  2. Metabolomics and Machine Learning Identify Novel Serum Biomarkers for Nasopharyngeal Carcinoma Diagnosis2025International Journal of Radiation Oncology*Biology*Physicsarticle
  3. Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study.2024Journal of Clinical Oncologyconference-abstract
  4. Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.2024Journal of Clinical Oncologyconference-abstract
  5. 32P Clinical efficacy and safety of an immune checkpoint inhibitor in combination with regorafenib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma2023ESMO Openarticle
  6. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncologyarticle
  7. Feasibility study of pharyngeal constrictor muscle sparing in proton radiotherapy for nasopharyngeal carcinoma based on MRI/CT fusion image2023Research Squarepreprint
  8. Predicting late radiation-induced xerostomia in nasopharyngeal carcinoma based on radiomics features extracted from T2WI images of parotids2023Radiation Medicine and Protectionarticle
  9. 1328P Association of socioeconomic disparities with nasopharyngeal carcinoma survival in an endemic area, China2022Annals of Oncologyarticle
  10. Abstract 5241: p38 MAPK/EGR1/PD-L1 axis promotes radiation resistance of nasopharyngeal carcinoma by enhancing immune evasion2022Cancer Researchconference-abstract
  11. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncologyconference-abstract
  12. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 65 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 2.2%.

Papers led
65
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 7720212022: 9920222023: 151520232024: 181820242025: 14142025

6 hospitals in Jinan for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Registry
    NCT06690216

    Age 18 years to Not stated (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  2. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  3. Recruiting
    A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06769113

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapyNeoadjuvant & combined treatmentImaging & AI
Departments in papersRadiation oncologyRadiology / nuclear medicinePathology / laboratory medicineMedical oncology
Papers it led65
  1. 18F-NOTA-FAPI-04 PET/CT metabolic parameters combined with hematological biomarkers predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.2026European journal of nuclear medicine and molecular imagingFree full text
  2. Neoadjuvant tislelizumab with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma.2026International journal of surgery (London, England)
  3. Identifying risk factors and evaluating therapeutic interventions for anastomotic recurrence in postoperative esophageal squamous cell carcinoma.2025BMC cancerFree full text
  4. Detecting radiation esophagitis using 18F-FAPI-04 PET/CT in patients with LA-ESCC treated with concurrent chemoradiotherapy.2025BMC cancerFree full text
  5. Predicting anastomotic leak in patients with esophageal squamous cell cancer treated with neoadjuvant chemoradiotherapy using a nomogram based on CT radiomic and clinicopathologic factors.2025BMC cancerFree full text
  6. Impact of radiation dose to immune cells on survival in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a retrospective analysis.2025BMC cancerFree full text
  7. Dual energy CT-derived quantitative parameters and hematological characteristics predict pathological complete response in neoadjuvant chemoradiotherapy esophageal squamous cell carcinoma patients.2025BMC gastroenterologyFree full text
  8. Development and validation a radiomics combined clinical model predicts treatment response for esophageal squamous cell carcinoma patients.2025BMC gastroenterologyFree full text
  9. The prognosis prediction value of CD69+ CD8+ tissue-resident memory T cell as a novel indicator of pathologic complete response heterogeneity following different neoadjuvant therapy regimen in esophageal squamous cell carcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  10. Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy.2025Frontiers in immunologyFree full text
  11. Tertiary lymphoid structures in esophageal cancer: a novel target for immunotherapy.2025Frontiers in immunologyFree full text
  12. Prognostic analysis of esophageal cancer patients after neoadjuvant therapy.2025Frontiers in immunologyFree full text
  13. CT-based delta-radiomics nomogram for predicting post-neoadjuvant chemoradiotherapy lymph node metastasis in esophageal squamous cell carcinoma: A feasibility study.2025Journal of cancer research and therapeutics
  14. Efficacy of neoadjuvant chemoimmunotherapy in locally advanced resectable esophageal cancer.2025Journal of cancer research and therapeutics
  15. Multi-task and multi-scale attention network for lymph node metastasis prediction in esophageal cancer.2025Medical & biological engineering & computing
  16. Postoperative Adjuvant Therapy Benefits Non-pCR Patients Rather Than pCR Patients for Locally Advanced ESCC: A Multicenter Real-World Study.2025Thoracic cancerFree full text
  17. The TDP-43/TP63 Positive Feedback Circuit Promotes Esophageal Squamous Cell Carcinoma Progression.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  18. Neoadjuvant radiation target volume definition in esophageal squamous cell cancer: a multicenter recommendations from Chinese experts.2024BMC cancerFree full text
  19. Association of effective dose to immune cells and vertebral marrow dose with hematologic toxicity during neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.2024BMC cancerFree full text
  20. A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.2024BMC cancerFree full text
  21. Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial.2024Cancer communications (London, England)RCTFree full text
  22. Single-cell transcriptomic analysis reveals the landscape of epithelial-mesenchymal transition molecular heterogeneity in esophageal squamous cell carcinoma.2024Cancer letters
  23. HRU-Net: A high-resolution convolutional neural network for esophageal cancer radiotherapy target segmentation.2024Computer methods and programs in biomedicine
  24. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.2024Frontiers in immunologyFree full text
  25. Tislelizumab for consolidation therapy in patients with pathologically residual Esophageal Squamous Cell Carcinoma after definitive concurrent Chemoradiotherapy: a multicenter, randomized, controlled phase II trial.2024Future oncology (London, England)RCTFree full text
  26. A Phase 1b Clinical Trial of Neoadjuvant Radio-immunotherapy for Esophageal Squamous Cell Cancer.2024International journal of radiation oncology, biology, physics
  27. Accurate location describe and management of lymph node recurrence after esophagectomy for thoracic esophageal squamous cell carcinoma: a retrospective cohort study.2024International journal of surgery (London, England)Free full text
  28. [18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial.2024Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  29. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer.2024Journal of translational medicineFree full text
  30. Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients.2024Nutrition (Burbank, Los Angeles County, Calif.)
  31. Comparison of neoadjuvant chemoradiotherapy versus chemoradiotherapy plus immunotherapy for esophageal squamous cell carcinoma in a real-world multicenter cohort: a propensity score matching study.2024Scientific reportsFree full text
  32. Assessing the Impact of a 1.5 T Transverse Magnetic Field in Radiotherapy for Esophageal Cancer Patients.2024Technology in cancer research & treatmentFree full text
  33. Radiomics-clinical nomogram for preoperative lymph node metastasis prediction in esophageal carcinoma.2024The British journal of radiologyFree full text
  34. The role of spleen radiomics model for predicting prognosis in esophageal squamous cell carcinoma patients receiving definitive radiotherapy.2024Thoracic cancerFree full text
  35. Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial.2023British journal of cancerRCTFree full text
  36. LINC01004-SPI1 axis-activated SIGLEC9 in tumor-associated macrophages induces radioresistance and the formation of immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma.2023Cancer immunology, immunotherapy : CIIFree full text
  37. TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism.2023Cancer immunology, immunotherapy : CIIFree full text
  38. Progression of precancerous lesions of esophageal squamous cell carcinomas in a high-risk, rural Chinese population.2023Cancer medicineFree full text
  39. YY1 modulates the radiosensitivity of esophageal squamous cell carcinoma through KIF3B-mediated Hippo signaling pathway.2023Cell death & diseaseFree full text
  40. Early detection of radiation-induced myocardial damage by [18F]AlF-NOTA-FAPI-04 PET/CT imaging.2023European journal of nuclear medicine and molecular imaging
  41. 18F-FAPI-04 PET/CT parameters predict PD-L1 expression in esophageal squamous cell carcinoma.2023Frontiers in immunologyFree full text
  42. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.2023Frontiers in immunologyFree full text
  43. Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma.2023Frontiers in immunologyFree full text
  44. Integrating Preoperative Computed Tomography and Clinical Factors for Lymph Node Metastasis Prediction in Esophageal Squamous Cell Carcinoma by Feature-Wise Attentional Graph Neural Network.2023International journal of radiation oncology, biology, physics
  45. Clinical Outcome-Related Cancer Pathways and Mutational Signatures in Patients With Unresectable Esophageal Squamous Cell Carcinoma Treated With Chemoradiotherapy.2023International journal of radiation oncology, biology, physics
  46. Do higher radiation doses improve survival for cervical esophageal squamous cell cancer patients treated with definitive chemoradiotherapy using intensity-modulated radiotherapy? A propensity-score matched analysis.2023Journal of cancer research and therapeutics
  47. The prognostic value of 11th Japanese classification and 8th AJCC staging systems in Chinese patients with esophageal squamous cell carcinoma.2023Journal of cardiothoracic surgeryFree full text
  48. Response Prediction Using 18F-FAPI-04 PET/CT in Patients with Esophageal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy.2023Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  49. Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report.2023MedicineFree full text
  50. Sarcopenia is associated with prognosis in patients with esophageal squamous cell cancer after radiotherapy or chemoradiotherapy.2022BMC gastroenterologyFree full text
  51. MiR-26b-5p in small extracellular vesicles derived from dying tumor cells after irradiation enhances the metastasis promoting microenvironment in esophageal squamous cell carcinoma.2022Cancer letters
  52. Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  53. Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma.2022International immunopharmacology
  54. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A randomized, multicenter, phase II clinical trial.2022International journal of cancerRCT
  55. PD-1 inhibitor monotherapy versus combination therapy: A real-world study of patients with recurrent or metastatic advanced esophageal squamous cell carcinoma after first-line chemotherapy.2022Journal of cancer research and therapeutics
  56. Integrated cohort of esophageal squamous cell cancer reveals genomic features underlying clinical characteristics.2022Nature communicationsFree full text
  57. The Hu antigen R/interferon-β axis modulates sensitivity of esophageal squamous cancer cells to cisplatin.2022Neoplasma
  58. Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures.2022Radiation oncology (London, England)RCTFree full text
  59. Bone marrow dosimetric analysis of lymphopenia in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy.2021Cancer medicineFree full text
  60. A nomogram to predict short-term outcome of radiotherapy or chemoradiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma.2021International immunopharmacology
  61. 3D Deep Learning Model for the Pretreatment Evaluation of Treatment Response in Esophageal Carcinoma: A Prospective Study (ChiCTR2000039279).2021International journal of radiation oncology, biology, physics
  62. Multiregion sequencing and subclonal analysis reveal intratumoral heterogeneity in esophageal squamous cell carcinoma.2021Journal of cancer research and therapeutics
  63. SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis.2021Journal of translational medicineFree full text
  64. Oncogenic SNORD12B activates the AKT-mTOR-4EBP1 signaling in esophageal squamous cell carcinoma via nucleus partitioning of PP-1α.2021Oncogene
  65. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.2021Radiation oncology (London, England)Free full text
All its trials on ClinicalTrials.gov, any status22
  1. Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.Status unknownNCT05323890Lead sponsorPhase 2Start 2022-04
  2. A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCCTerminatedNCT02721550Lead sponsorPhase 4Start 2016-08
  3. A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCCTerminatedNCT02721576Lead sponsorPhase 4Start 2016-07
  4. A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCCCompletedNCT02721563Lead sponsorPhase 4Start 2016-02
  5. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell CarcinomaStatus unknownNCT02409186Lead sponsorPhase 3Start 2015-03
  6. Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell CarcinomaCompletedNCT00815308Lead sponsorPhase 2Start 2009-01
  7. IMRT/Pemetrexed/Cisplatin in Esophageal CancerStatus unknownNCT01630174Lead sponsorStart 2009-10
  8. Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant TumorsEnrolling by invitationNCT06690216Lead (inferred)Phase 1/Phase 2Start 2024-03
  9. A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard TherapyRecruitingNCT06769113Study sitePhase 2Start 2025-01
  10. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  11. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  12. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  13. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCStatus unknownNCT05221658Study sitePhase 2Start 2022-08
  14. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  15. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  16. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  17. Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).Status unknownNCT04063683Study sitePhase 2Start 2019-10
  18. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  19. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  20. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  21. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  22. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
More papers found outside PubMed (not counted)87
  1. 2124P Sintilimab plus chemoradiotherapy as first-line treatment for stage IV ESCC with non-regional node metastases only: A phase II clinical trial2025Annals of Oncologyarticle
  2. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncologyarticle
  3. A Comparative Study of Automated and Manual Contouring in Radiomic Models for Lymph Node Assessment in Esophageal Squamous Cell Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  4. Combined PD-L1 expression and PD-1+ CD8 T cells to predict immunotherapy outcomes in esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyconference-abstract
  5. Effects of lymphatic ablation approaches on immunotherapy efficacy in esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyarticle
  6. Failure patterns and the value of postoperative adjuvant radiotherapy in esophageal squamous cell carcinoma patients treated with neoadjuvant immunotherapy combined with chemotherapy.2025Journal of Clinical Oncologyarticle
  7. Identifying Risk Factors and Evaluating Therapeutic Interventions for Anastomotic Recurrence in Postoperative Esophageal Squamous Cell Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  8. Impact of Muscle Mass Loss on Survival during Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center Retrospective Study in China (TIMES Study)2025International Journal of Radiation Oncology*Biology*Physicsarticle
  9. Impact of muscle mass loss on survival during neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma: A multi-center retrospective study in China (TIMES study).2025Journal of Clinical Oncologyarticle
  10. Knockdown of DNAJC12 slows tumor progression and affects tumor radiosensitivity in esophageal squamous cell carcinoma2025Molecular & cellular biomechanicsarticle
  11. Nasal cavity and brain metastases from esophageal carcinoma detected by 68 Ga-FAPI PET/CT2025Journal of Nuclear Medicine and Molecular Imagingarticle
  12. Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial.2025Journal of Clinical Oncologyconference-abstract
  13. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncologyarticle
  14. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncologyconference-abstract
  15. Quantitative Parameters Derived from Dual Energy CT and Hematological Features Predict Pathological Complete Response in Neoadjuvant Chemoradiotherapy Esophageal Squamous Cell Carcinoma Patients2025International Journal of Radiation Oncology*Biology*Physicsarticle
  16. The efficacy and safety of adjuvant immunotherapy after neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal squamous cell carcinoma: A real-world study.2025Journal of Clinical Oncologyarticle
  17. The role of ADAR1-mediated A-to-I RNA editing and non-editing functions in radioresistance of esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyarticle
  18. Tumor location affects the outcome of radiation therapy for esophageal squamous cell carcinoma: A Retrospective Study, Systematic Review, and Meta-analysis2025Research Squarepreprint
  19. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncologyarticle
  20. 1452P Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial2024Annals of Oncologyarticle
  21. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncologyarticle
  22. A-to-I RNA Editing of C16orf46 and Radiation Resistance by Regulating Cell Cycle Arrest and Apoptosis in Esophageal Cancer2024International Journal of Radiation Oncology*Biology*Physicsarticle
  23. Abstract 2876: Spatial immune cell atlas predicts the sensitivity to neoadjuvant PD-1 blockade treatment combined with radiotherapy in resectable esophageal squamous cell carcinoma2024Cancer Researchconference-abstract
  24. Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1st-RT): A single-arm, open-label, phase 2 trial.2024Journal of Clinical Oncologyconference-abstract
  25. Dual-Omics Combined Hematological Parameters Model Predicts Pathological Complete Response in Esophageal Squamous Cell Carcinoma Patients after Neoadjuvant Chemoradiotherapy:A Multicenter Study2024SSRN Electronic Journalpreprint
  26. First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.2024Journal of Clinical Oncologyconference-abstract
  27. ITGA5 and Radioresistance through DNA Damage Repair in Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  28. Longitudinal CT Feature-Based Model for Predicting Local Recurrence Free Survival in Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: A Multicenter Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  29. Longitudinal evaluation of circulating tumor cells in operable locally advanced esophageal squamous cell carcinoma2024Research Squarepreprint
  30. Neoadjuvant Tislelizumab Combined with Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase II Study and Exploration of Immunologic Features2024International Journal of Radiation Oncology*Biology*Physicsarticle
  31. Pathologic Response Prediction Value of18f-Fapi PET/CT in ESCC Treated with Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial2024International Journal of Radiation Oncology*Biology*Physicsarticle
  32. Pathological Response and Survival Outcome after Neoadjuvant Chemoradiotherapy vs. Immunochemotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  33. Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.2024Journal of Clinical Oncologyconference-abstract
  34. Revolutionizing outcome prediction for immunotherapy with vision transformer-based pathomics signature in esophageal squamous cell cancer.2024Journal of Clinical Oncologyconference-abstract
  35. Safety and Efficacy of Neoadjuvant Chemoradiotherapy with Concurrent Weekly Versus Tri-Weekly Cisplatin/Nab-Paclitaxel in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  36. SnoRNAs and Radiotherapy Resistance in Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  37. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncologyarticle
  38. 95P A single-arm, multicenter phase II trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)2023Immuno-Oncology Technologyarticle
  39. A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  40. Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-2023Cancer Researchconference-abstract
  41. CT-Based Radiomics Combined with Genomics may Predict Survival in Esophageal Cancer Patients Receiving Definitive Chemoradiotherapy2023International Journal of Radiation Oncology*Biology*Physicsarticle
  42. Development and Validation of a Radiomics-Based Model to Predict Overall Survival after Definitive Chemoradiotherapy in Patients with Esophageal Cancer2023International Journal of Radiation Oncology*Biology*Physicsarticle
  43. Effect of Histopathological Regression of Tumor and Lymph Node on the Progression of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy2023International Journal of Radiation Oncology*Biology*Physicsarticle
  44. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncologyconference-abstract
  45. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncologyconference-abstract
  46. Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study.2023Journal of Clinical Oncologyconference-abstract
  47. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  48. Optimizing Disease-Free Survival Prognosis: The Tumor Regression Grade Combined with Post-Neoadjuvant Pathologic Lymph Node Category (TRG -ypN) Novel Staging Approach Post-Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esop2023SSRN Electronic Journalpreprint
  49. Predicting Radiation Esophagitis using 18F-FAPI-04 PET/CT in Patients with LA-ESCC Treated with Concurrent Chemoradiotherapy2023International Journal of Radiation Oncology*Biology*Physicsarticle
  50. Study on the Dynamic Changes of Myocardial Injury Markers in Radiotherapy for Esophageal Carcinoma and Its Correlation with Cardiac Dosimetry2023International Journal of Radiation Oncology*Biology*Physicsarticle
  51. TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase Ⅱ trial.2023Journal of Clinical Oncologyconference-abstract
  52. The Role of CT-Based Radiomics Nomogram in Differential Diagnosis of Immune Checkpoint Inhibitor-Related Pneumonitis from Radiation Pneumonitis for Patients with ESCC2023International Journal of Radiation Oncology*Biology*Physicsarticle
  53. Treatment Response Prediction Using a Combination of Hematological Biomarkers and CT Deep Learning Radiomics in Locally Advanced Esophageal Squamous Cell Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  54. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncologyconference-abstract
  55. 105P Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study2022Immuno-Oncology Technologyarticle
  56. 164P TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter phase Ⅱ trial2022Immuno-Oncology Technologyarticle
  57. Abstract 6270: Integrating spatial transcriptomics and single-cell RNA-seq reveal the tumorigenesis and heterogeneity of esophageal squamous cell carcinoma2022Cancer Researchconference-abstract
  58. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  59. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  60. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  61. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  62. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  63. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  64. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  65. CT-Based Deep Learning Model for Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Patients Received Concurrent Chemo-Radiotherapy: A Multicenter Study2022International Journal of Radiation Oncology*Biology*Physicsarticle
  66. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  67. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  68. RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling2022Figsharedataset
  69. Sintilimab after Concurrent Chemoradiotherapy in Locoregional Recurrent ESCC after Definitive Treatment: A Single-Arm, Phase II Study2022International Journal of Radiation Oncology*Biology*Physicsarticle
  70. Two-Stage Phase II Study of Envafolimab Combined with Endostar and Concurrent Chemoradiotherapy in Treatment of Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: Preliminary Results of Stage 12022International Journal of Radiation Oncology*Biology*Physicsarticle
  71. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2022Journal of Clinical Oncologyconference-abstract
  72. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  73. CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  74. Co-graph Attention Reasoning Based Imaging and Clinical Features Integration for Lymph Node Metastasis Prediction2021Lecture notes in computer scienceconference-paper
  75. Corrigendum: Low Lymphocyte Count Is Associated With Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients2021Frontiers in Oncologyerratum
  76. Genomic Profiling Identified Prognostic Biomarkers of Definitive Chemo-Radiotherapy Response in Esophageal Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle
  77. IDDF2021-ABS-0158 Small extracellular vesicles derived from esophageal squamous cell carcinoma promote immunosuppressive effects of myeloid-derived suppressor cells after ionizing radiation2021Gutconference-paper
  78. Improved lymph node metastasis prediction from preoperative esophageal squamous cell cancer CT by graph attention convolutional neural network (GACNN).2021Journal of Clinical Oncologyconference-abstract
  79. Integrating Preoperative CT and Clinical Factors for Lymph Node Metastasis Prediction in Esophageal Cancer by Feature-Wise Attentional Graph Neural Network (FAGNN)2021International Journal of Radiation Oncology*Biology*Physicsarticle
  80. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study2021Annals of Oncologyconference-abstract
  81. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  82. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  83. Nomograms Predicting Response and Survival of Esophageal Squamous Cell Carcinoma Patients Treated With Anti-PD-1 Therapy2021International Journal of Radiation Oncology*Biology*Physicsarticle
  84. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract
  85. The Predictive Value of Tumor Volume, Inflammatory Biomarkers, and Their Dynamic Changes on Early Tumor Response for Elderly Patients With Esophageal Squamous Cell Carcinoma Underwent Radiotherapy2021Research Squarepreprint
  86. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncologyconference-abstract
  87. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 59 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
59
2021–2025
Trials led
10
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 8820212022: 8820222023: 131320232024: 131320242025: 16162025

6 hospitals in Jinan for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06841172

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  2. Recruiting
    BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07062055

    Age 18 years to 70 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  3. Recruiting
    Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
    Phase
    Phase 2
    Started
    2023-10
    Registry
    NCT06904014

    Age 18 years to 70 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  4. Not yet recruiting
    Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07352007

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  5. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  6. Recruiting
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07391839

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou

  7. Recruiting
    A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06530251

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan

  8. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesLocal treatment (ablation, TACE, HAIC)Recurrence & prognosisImmunotherapy & targeted drugs
Departments in papersRadiation oncologyMedical oncologyRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led59
  1. Hepatic arterial infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus: a multicenter, propensity score matching comparative study.2026Hepatology international
  2. Hepatic Arterial Infusion Chemotherapy Enhances the Efficacy of Lenvatinib Plus PD-1 Inhibitors in Hepatocellular Carcinoma Patients with Tumor Thrombosis in the Inferior Vena Cava and/or Right Atrium.2025Academic radiology
  3. H3K36me3-Guided m6A Modification of Oncogenic L1CAM-AS1 Drives Macrophage Polarization and Immunotherapy Resistance in Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Oncogenic RBM19 modulated by MAX-mediated allelic transcription regulation in hepatocellular carcinoma progression.2025Archives of biochemistry and biophysics
  5. Integrated functional genomics-identified LYRM4 promotes fumarate accumulation and hepatocellular carcinoma progression.2025Archives of biochemistry and biophysics
  6. Curcumin induces ferroptosis in hepatocellular carcinoma by regulating the P62-KEAP1-NRF2-signaling pathway.2025BMC cancerFree full text
  7. Clinical efficacy of TACE using coil or gelatin sponge combined with targeted therapy in the treatment of giant hepatocellular carcinoma with arterioportal fistulas.2025BMC gastroenterologyFree full text
  8. Integrated functional genomics-identified DEAF1 in oxidative stress and hepatocellular carcinoma development.2025Carcinogenesis
  9. Impact of microwave ablation on survival rates and recurrence in hepatic malignant tumors.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  10. Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma.2025Clinical and experimental medicineFree full text
  11. HCC-derived CX3CL1 affects hepatocellular carcinoma prognosis and CX3CR1 + MDSC infiltration.2025European journal of medical researchFree full text
  12. C-reactive protein flare: a promising prognostic predictor for patients with hepatocellular carcinoma treated with TACE combined with lenvatinib and immune checkpoint inhibitors.2025Frontiers in immunologyFree full text
  13. Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.2025Frontiers in immunologyFree full text
  14. CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma cases: a multi-center study.2025Hepatology international
  15. Maintaining First-Line Therapy Plus Radiation Therapy May Prolong Progression-Free Survival and Delay Second-Line Therapy for Oligoprogressive Hepatocellular Carcinoma.2025International journal of radiation oncology, biology, physics
  16. Targeting NOTCH1-KEAP1 axis retards chronic liver injury and liver cancer progression via regulating stabilization of NRF2.2025Journal of experimental & clinical cancer research : CRFree full text
  17. Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression.2025Journal of hepatology
  18. Genome-wide functional integration identified MAZ-controlled RPS14 dysregulation in hepatocellular carcinoma.2024Archives of toxicology
  19. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.2024BMC cancerFree full text
  20. Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma.2024BMC cancerFree full text
  21. Clinical study on conversion therapy of hepatocellular carcinoma - summary and comparison of clinical data from a single center of consecutive four years.2024BMC gastroenterologyFree full text
  22. Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma.2024Biochimica et biophysica acta. Reviews on cancer
  23. Machine learning-based decision support model for selecting intra-arterial therapies for unresectable hepatocellular carcinoma: A national real-world evidence-based study.2024British journal of cancerFree full text
  24. Expression and clinical significance of NLRC5 in hepatocellular carcinoma.2024Cancer biology & therapyFree full text
  25. CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib.2024Cancer medicineFree full text
  26. Immune cell dynamics and the impact on the efficiency of transvascular antitumor interventional therapies in hepatocellular carcinoma patients.2024Frontiers in immunologyFree full text
  27. Molecular subtypes of disulfidptosis-regulated genes and prognosis models for predicting prognosis, tumor microenvironment infiltration, and therapeutic response in hepatocellular carcinoma.2024International journal of biological macromolecules
  28. Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study.2024Journal of cancer research and therapeutics
  29. Systemic Chemotherapy with or without Hepatic Arterial Infusion Chemotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Oligometastasis: A Propensity Score-Matched Analysis.2024Journal of vascular and interventional radiology : JVIR
  30. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial.2024Nature communicationsFree full text
  31. Epirubicin may enhance the inhibition of hepatocellular carcinoma induced by iodine-125 seeds through downregulating WNT pathway.2023Asia-Pacific journal of clinical oncology
  32. Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy.2023BMC cancerFree full text
  33. Real-world practice of conversion surgery for unresectable hepatocellular carcinoma - a single center data of 26 consecutive patients.2023BMC cancerFree full text
  34. Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis.2023BMC gastroenterologyFree full text
  35. Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma.2023Cancer immunology, immunotherapy : CIIFree full text
  36. Super Enhancer-Regulated LncRNA LINC01089 Induces Alternative Splicing of DIAPH3 to Drive Hepatocellular Carcinoma Metastasis.2023Cancer research
  37. Matrix metalloproteinase gene mutations and bioinformatics of telocytes in hepatocellular carcinoma.2023Cell biology international
  38. Tumour-derived exosomal lncRNA SNHG16 induces telocytes to promote metastasis of hepatocellular carcinoma via the miR-942-3p/MMP9 axis.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  39. Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  40. Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma.2023Hepatology international
  41. Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: Efficacy, safety, and prognostic factors.2023Journal of cancer research and therapeutics
  42. Characterization of disease-associated microbiota in hepatocellular carcinoma.2023Journal of cancer research and therapeutics
  43. Effect of type 2 diabetes on liver images of GD-EOB-DTPA-enhanced MRI during the hepatobiliary phase.2023Scientific reportsFree full text
  44. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.2022BMJ openFree full text
  45. N6 -methyladenosine-modified lncRNA ARHGAP5-AS1 stabilises CSDE1 and coordinates oncogenic RNA regulons in hepatocellular carcinoma.2022Clinical and translational medicineFree full text
  46. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.2022European journal of pharmacology
  47. Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.2022Frontiers in endocrinologyFree full text
  48. Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs.2022Frontiers in immunologyFree full text
  49. Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors.2022Journal of immunology researchFree full text
  50. Geriatric nutritional risk index as a prognostic factor in patients with hepatocellular carcinoma following transarterial chemoembolization: A retrospective study.2022MedicineFree full text
  51. Identifying a Novel Endoplasmic Reticulum-Related Prognostic Model for Hepatocellular Carcinomas.2022Oxidative medicine and cellular longevityFree full text
  52. LncRNA H19 modulated by miR-146b-3p/miR-1539-mediated allelic regulation in transarterial chemoembolization of hepatocellular carcinoma.2021Archives of toxicology
  53. N6-methyladenosine reader YTHDC2 and eraser FTO may determine hepatocellular carcinoma prognoses after transarterial chemoembolization.2021Archives of toxicology
  54. Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1.2021BMC cancerFree full text
  55. A preliminary investigation of re-evaluating the irradiation dose in hepatocellular carcinoma radiotherapy applying 4D CT and deformable registration.2021Journal of applied clinical medical physicsFree full text
  56. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.2021Journal of cancer research and therapeutics
  57. Type of Necrosis Influences Prognosis in Hepatocellular Carcinoma After the First Transarterial Chemoembolization.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  58. Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.2021MedicineFree full text
  59. Serum-derived exosomes function as tumor antigens in patients with advanced hepatocellular carcinoma.2021Molecular immunology
All its trials on ClinicalTrials.gov, any status19
  1. Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCCRecruitingNCT06841172Lead sponsorPhase 3Start 2025-07
  2. BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or OligometastasesRecruitingNCT07062055Lead sponsorPhase 2Start 2025-07
  3. SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular CarcinomaSuspendedNCT07274774Lead sponsorPhase 2Start 2025-11
  4. Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver CancerCompletedNCT06261047Lead sponsorStart 2024-03
  5. A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular CarcinomaStatus unknownNCT05185531Lead sponsorPhase 1Start 2022-03
  6. A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular CarcinomaCompletedNCT05099848Lead sponsorPhase 2Start 2021-03
  7. Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular CarcinomaStatus unknownNCT01556815Lead sponsorPhase 2Start 2012-05
  8. TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular CarcinomaStatus unknownNCT01605734Lead sponsorPhase 2Start 2012-07
  9. Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable HepatocellularNot yet recruitingNCT07352007Lead (inferred)Phase 2Start 2025-12
  10. Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCCRecruitingNCT06904014Lead (inferred)Phase 2Start 2023-10
  11. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.RecruitingNCT07391839Study sitePhase 1Start 2025-08
  12. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  13. A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)RecruitingNCT06530251Study sitePhase 1/Phase 2Start 2024-09
  14. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  15. A Phase II Study of AK104 Plus Lenvatinib and TACE in HCCActive, not recruitingNCT05319431Study sitePhase 2Start 2022-06
  16. Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC PatientsActive, not recruitingNCT05377034Study sitePhase 2Start 2022-10
  17. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  18. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  19. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 33 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
33
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 8820232024: 7720242025: 13132025

8 hospitals in Jinan for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07007182

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  2. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  3. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  4. Recruiting
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06873659

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an

  5. Recruiting
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    Phase
    Phase 2/Phase 3
    Started
    2024-02
    Registry
    NCT06221748

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou

  6. Recruiting
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06155383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou

  7. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChemotherapy & combined treatmentImmunotherapy & targeted drugsNutrition & recovery
Departments in papersRadiation oncologyMedical oncologyGastroenterology / hepatologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led33
  1. Overcoming Photothermal Resistance of Gastric Cancer by Bionic 2D Iron-Based Nanoplatforms with Precise CRISPR/Cas9 Delivery.2025ACS nano
  2. Machine learning-based integration develops a disulfidptosis-related lncRNA signature for improving outcomes in gastric cancer.2025Artificial cells, nanomedicine, and biotechnology
  3. Twenty-four-month Progression-free Survival in HER2-amplified Advanced Gastric Cancer with Brain Metastases after Trastuzumab Deruxtecan Treatment: A Case Report and Literature Review.2025Current cancer drug targets
  4. Improved Sampling Method to Enhance the Positive Rate of HER2 Detection in Gastric Cancer.2025Discovery medicine
  5. Exploring the possible mechanism of low-dose naloxone exposure improving the immune microenvironment of gastric cancer tumors.2025Frontiers in immunologyFree full text
  6. GABRD Accelerates Tumour Progression via Regulating CCND1 Signalling Pathway in Gastric Cancer.2025Journal of cellular and molecular medicineFree full text
  7. Single-cell RNA Sequencing Analysis Reveals Cancer-associated Fibroblast Signature for Prediction of Clinical Outcomes and Immunotherapy in Gastric Cancer.2025Journal of immunotherapy (Hagerstown, Md. : 1997)
  8. Key Lipid Reprogramming Revealed in Gastric Signet Ring Cell Carcinoma by Spatial Mass Spectrometry Metabolomics.2025Journal of the American Society for Mass Spectrometry
  9. Non-coding RNAs in gastric cancer: mechanisms and therapeutic prospects.2025Molecular cancerFree full text
  10. METTL3 Promotes Gastric Cancer Progression via Modulation of FNTA-Mediated KRAS/ERK Signaling Activation.2025Molecular cancer research : MCR
  11. Regulatory mechanisms of the Hippo/YAP axis by G-protein coupled estrogen receptor in gastric signet-ring cell carcinoma.2025Neoplasia (New York, N.Y.)Free full text
  12. Patterns of Recurrence After D2 Radical Surgery for Gastric Cancer: Implications for Postoperative Radiation Therapy.2025Practical radiation oncology
  13. Oxaliplatin accelerates immunogenic cell death by activating the cGAS/STING/TBK1/IRF5 pathway in gastric cancer.2025The FEBS journal
  14. Effects of perioperative low-dose naloxone on the immune system in patients undergoing laparoscopic-assisted total gastrectomy: a randomized controlled trial.2024BMC anesthesiologyRCTFree full text
  15. Overall and cause-specific mortality among patients diagnosed with gastric precancerous lesions in Sweden between 1979 and 2014: an observational cohort study.2024BMC medicineFree full text
  16. Study on correlation between perioperative cognitive function and nutritional status in elderly patients with gastric cancer.2024Experimental gerontology
  17. Super-enhancers: Implications in gastric cancer.2024Mutation research. Reviews in mutation research
  18. KBTBD2 promotes proliferation and migration of gastric cancer via activating EGFR signaling pathway.2024Pathology, research and practice
  19. Acyltransferase zinc finger DHHC-type containing 2 aggravates gastric carcinoma growth by targeting Nrf2 signaling: A mechanism-based multicombination bionic nano-drug therapy.2024Redox biologyFree full text
  20. Efficacy and safety of anti-programmed death-1 antibody-based combination therapy in advanced or metastatic gastric or gastroesophageal junction cancer in Chinese patients: A real-world study.2024Science progressFree full text
  21. LINC01226 promotes gastric cancer progression through enhancing cytoplasm-to-nucleus translocation of STIP1 and stabilizing β-catenin protein.2023Cancer letters
  22. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.2023Cancer medicineFree full text
  23. CircPDIA4 Induces Gastric Cancer Progression by Promoting ERK1/2 Activation and Enhancing Biogenesis of Oncogenic circRNAs.2023Cancer research
  24. Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer.2023Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  25. OASL knockdown inhibits the progression of stomach adenocarcinoma by regulating the mTORC1 signaling pathway.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  26. LINC00240 in the 6p22.1 risk locus promotes gastric cancer progression through USP10-mediated DDX21 stabilization.2023Journal of experimental & clinical cancer research : CRFree full text
  27. Single-cell analysis of gastric signet ring cell carcinoma reveals cytological and immune microenvironment features.2023Nature communicationsFree full text
  28. The ASH1L-AS1-ASH1L axis controls NME1-mediated activation of the RAS signaling in gastric cancer.2023Oncogene
  29. Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report.2022Frontiers in immunologyFree full text
  30. Construction of a Cuprotosis-Related Gene-Based Model to Improve the Prognostic Evaluation of Patients with Gastric Cancer.2022Journal of immunology researchFree full text
  31. Effect of LAMA4 on Prognosis and Its Correlation with Immune Infiltration in Gastric Cancer.2021BioMed research internationalFree full text
  32. LncPSCA in the 8q24.3 risk locus drives gastric cancer through destabilizing DDX5.2021EMBO reportsFree full text
  33. Comparison of CellSearch and Circulating Tumor Cells (CTC)-Biopsy Systems in Detecting Peripheral Blood Circulating Tumor Cells in Patients with Gastric Cancer.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
Chinese-language papers (not in the count)1
  1. [Perioperative radiotherapy on local-advanced gastric cancer--From the perspective of failure pattern].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status19
  1. The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.CompletedNCT03384511Lead sponsorPhase 4Start 2016-09
  2. Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric CancerRecruitingNCT07007182Lead (inferred)Phase 2Start 2025-10
  3. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  4. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  5. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsRecruitingNCT06873659Study sitePhase 1Start 2025-02
  6. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Study sitePhase 2/Phase 3Start 2024-02
  7. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Study sitePhase 2Start 2023-11
  8. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  9. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.Active, not recruitingNCT06116136Study sitePhase 1/Phase 2Start 2024-08
  10. To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT05253053Study sitePhase 1/Phase 2Start 2022-04
  11. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  12. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.TerminatedNCT05188209Study sitePhase 2Start 2021-12
  13. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  14. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingNCT04704934Study sitePhase 3Start 2021-05
  15. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  16. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  17. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  18. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  19. Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedNCT03427814Study sitePhase 2Start 2018-07

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Jinan for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Jinan for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

24 hospitals in Jinan for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Papers it led1
  1. Identification of Prognostic RBPs in Osteosarcoma.2021Technology in cancer research & treatment
Earlier papers (2016–2020)2
  1. Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.2020Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  2. Serum CEACAM1 Level Is Associated with Diagnosis and Prognosis in Patients with Osteosarcoma.2016PloS one

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

4 hospitals in Jinan for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 4 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025

9 hospitals in Jinan for neuroblastoma352 hospitals in China for neuroblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
    Phase
    Phase 1
    Started
    2022-12
    Registry
    NCT05562024

    Age 1 year to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesJinan, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

5 hospitals in Jinan for Ewing sarcoma139 hospitals in China for Ewing sarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06340204

    Age 8 years to 40 years (registered criteria)

    Led by Peking University People's Hospital; 2 listed hospitals as study sitesBeijing, Jinan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing SarcomaRecruitingNCT06340204Study sitePhase 1Start 2024-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

7 hospitals in Jinan for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  2. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  3. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantKidney & bone complications
Departments in papersMedical oncologyRadiation oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Jinan for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

山东省肿瘤医院

Shandong Cancer Hospital and Institute

济南

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Shandong Cancer Hospital; Shandong Cancer Hospital Affiliated to Shandong University; Shandong University Cancer Center; Shandong Cancer Hospital & Institute; Shandong Cancer Hospital And Institute; Shandong Cancer Hospital affiliated to Shandong University Jinan; Shandong Cancer Hospital Affiliated to Shandong University of Jinan; Shandong Cancer Hospital and Institute (HL)

Suggest a correctionDownload the data